Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6048653 | 0.88 | TSHR (0.42) | TSHRPTPN1LMNAMEN1KMT2A | |
| SCHEMBL27432594 | 0.82 | TSHR (0.37) | TSHRPTPN1ALDH1A1LMNAMEN1 | |
| SCHEMBL17617136 | 0.79 | ALDH1A1 (0.39) | TSHRALDH1A1LMNA | |
| SCHEMBL17617144 | 0.79 | TSHR (0.41) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL17617191 | 0.79 | TSHR (0.41) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL28363839 | 0.78 | MEN1 (0.43) | TSHRPTPN1ALDH1A1LMNAMEN1 | |
| SCHEMBL17617197 | 0.78 | TSHR (0.40) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL17617145 | 0.78 | TSHR (0.40) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL452863 | 0.78 | TSHR (0.37) | TSHRPTPN1LMNAMEN1KMT2A | |
| SCHEMBL17617138 | 0.76 | ALDH1A1 (0.46) | TSHRALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083341-A1 | METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE | API CORPORATION (JP) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083341-A1 | METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE | MGMT, GSTA1, CBS | TSHR 1898/4885PTPN1 3076/4885ALDH1A1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.